Clinical trial
Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity
Opening soon · Not applicable · 1 countries · Registry ID NCT06775093
Opening soonNot applicableInterventional
What this study is about
The goal of this clinical trial is to examine whether benalutide combined with metformin and healthy lifestyle education in women with PCOS and obesity prior to fertility treatment improves live birth rate and other reproductive, maternal and perinatal outcomes compared to metformin plus healthy lifestyle education.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to 40 Years
SexFemale
Healthy volunteersNot accepted
ConditionPolycystic Ovary Syndrome, Obesity, Infertility, Female
Full registry criteria
Inclusion Criteria: Women with a wish to conceive; Women with PCOS (Rotterdam criteria); 28 kg/m2≤BMI\<35kg/m2; Exclusion Criteria: Women with medical morbidity; Endocrine disorders; Abnormalities in liver and kidney function; Other medications such as glucocorticoids, anti-androgen drugs ;(spironolactone, cyproterone acetate, flutamide, etc.) within the last 3 months; Acute infections, severe cardiovascular disease, malignant tumors; Ongoing weight loss therapy (\>5% weight loss in the last 3 months) or history of gastrointestinal surgery; Uterine anomalies or untreated tubal hydrosalpinx; Receiving a donor oocyte or donor sperm cycle; Chromosome abnormality or recurrent miscarriage; planning preimplantation genetic testing (PGT); Any other contraindications to fertility treatment; Allergic to or contraindicated for GLP-1 class medications.
Treatments and study arms
GLP-1 receptor agonist
Drug
3 months
Metformin
Drug
3 months
healthy lifestyle education
Behavioral
3 months
Primary outcomes
Live birth rate18 months